New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Law enforcement officers are conducting searches in case of possible fraud during fundraising for the treatment of spinal ...

US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Children suffering from Spinal Muscular Atrophy (SMA) – a rare but debilitating genetic condition – are being denied a simple ...